Proteolysis-targeting chimeras (PROTACs) have been an area of intensive research with the
potential to extend drug space not target to traditional molecules. In the last half decade, we …

Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the
progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta …

The global fight against Human Immunodeficiency Virus (HIV) and related viral infections
stands at a pivotal juncture, demanding groundbreaking therapeutic strategies. Facing the …

Lastly, the emergence of viral resistance is a concern when developing antiviral therapies.[7]
Continuous exposure to PROTACs could lead to the selection of viral mutants with altered …

Personalized cancer immunotherapies, combined with nanotechnology (nano‐vaccines),
are revolutionizing cancer treatment strategies, explicitly targeting Human papilloma virus …

Abstract Proteolysis Targeting Chimeras (PROTACs) represent a significant advancement in
therapeutic drug development by leveraging the ubiquitin‐proteasome system to enable …

In the realm of cancer immunotherapy, a profound evolution has ushered in sophisticated
strategies that encompass both traditional cancer vaccines and emerging viral vaccines …

Recent advancements in neuroendocrinology challenge the long‐held belief that hormonal
effects are confined to perivascular tissues and do not extend to the central nervous system …

The evolving landscape of personalized medicine necessitates a shift from traditional
therapeutic interventions towards precision‐driven approaches. Embracing this paradigm …

The burgeoning global mortality rates attributed to cancer have precipitated a critical
reassessment of conventional therapeutic modalities, most notably chemotherapy, due to …